4 studies found for: encorafenib OR lgx818 | Open Studies
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
|3||Not yet recruiting||
Open Label, Multicentre Study of Encorafenib + Binimetinib + PD (Programmed Cell Death Protein) -1 Antibody Pembrolizumab
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
† Study has passed its completion date and status has not been verified in more than two years.